参考文献/References:
[1].Shen Y,Cai R,Sun J,et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men:a systematic review and meta-analysis[J]. Endocrine,2017,55(1):66-76.
[2].Rao Kondapally Seshasai S,Kaptoge S,Thompson A,et al. Diabetes mellitus,fasting glucose,and risk of cause specific death[J]. N Engl J Med,2011,364(9):829-841.
[3].Poredos P,Spirkoska A,Lezaic L,et al. Patients with an inflamed atherosclerotic plaque have increased levels of circulating inflammatory markers[J]. J Atheroscler Thromb,2017,24(1):39-46.
[4].Candido R,Bernardi S,Allen TJ. Linking diabetes and atherosclerosis[J]. Expert Rev Endocrinol Metab,2009,4(6):603-624.
[5].Rask-Madsen C,Li Q,Freund B,et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice[J]. Cell Metab,2010,11(5):379-389.
[6].Kernan WN,Viscoli CM,Furie KL,et al. Pioglitazone after ischemic stroke or transient ischemic attack[J]. N Engl J Med,2016,374(14):1321-1331.
[7].Luo JQ,Ren H,Banh HL,et al. The associations between apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphisms and the risk of coronary artery disease in patients with type 2 diabetes mellitus[J]. Front Physiol,2017,8:1031.
[8].Emerging Risk Factors Collaboration,Erqou S,Kaptoge S,et al. Lipoprotein(a) concentration and the risk of coronary heart disease,stroke,and nonvascular mortality[J]. JAMA,2009,302(4):412-423.
[9].Clarke R,Peden JF,Hopewell JC,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease[J]. N Engl J Med,2009,361(26):2518-2528.
[10].Kamstrup PR,Tybjaerg-Hansen A,Steffensen R,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J]. JAMA, 2009,301(22):2331-2339.
[11].Libby P. Interleukin-1 beta as a target for atherosclerosis therapy:biological basis of CANTOS and beyond[J]. J Am Coll Cardiol,2017,70(18):2278-2289.
[12].Libby P, Hansson GK. Taming immune and inflammatory responses to treat atherosclerosis[J]. J Am Coll Cardiol,2018,71(2):173-176.
[13].Sun Y,He J,Tian J,et al. Association of circulating levels of neopterin with non-culprit plaque vulnerability in CAD patients an angiogram, optical coherent tomography and intravascular ultrasound study[J]. Atherosclerosis,2015,241(1):138-142.
[14].Wu XF,Yang M,Qu AJ,et al. Level of pregnancy-associated plasma protein—A correlates with coronary thin-cap fibroatheroma burden in patients with coronary artery disease:novel findings from 3-vessel virtual histology intravascular ultrasound assessment[J]. Medicine,2016,95(3):e2563.
[15].Gleissner CA,Erbel C,Linden F,et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality:insights from the LURIC study[J]. Atherosclerosis,2017,260:121-129.
[16].Andersson C,Enserro D,Sullivan L,et al. Relations of circulating GDF-15,soluble ST2, and troponin-I concentrations with vascular function in the community:the Framingham Heart Study[J]. Atherosclerosis,2016,248:245-251.
[17].Viktorinova A,Svitekova K,Stecova A,et al. Relationship between selected oxidative stress markers and lipid risk factors for cardiovascular disease in middle-aged adults and its possible clinical relevance[J]. Clin Biochem,2016,49(12):868-872.
[18].Zargari M,Sharafeddin F,Mahrooz A,et al. The common variant Q192R at the paraoxonase 1(PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes[J]. Exp Biol Med,2016,241(14):1489-1496.
[19].Chistiakov DA,Melnichenko AA,Orekhov AN,et al. Paraoxonase and atherosclerosis-related cardiovascular diseases[J]. Biochimie,2017,132:19-27.
[20].Wu D,Wu C,Zhong Y. The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy[J]. J Cell Mol Med,2018,22(9):4283-4291.
[21].Crow JA,Meek EC,Wills RW,et al. A case-control study:the association of serum paraoxonase 1 activity and concentration with the development of type 2 diabetes mellitus[J]. Diabates Metab Res Rev,2018,34(3):e2967.
[22].Liu G,Ding M,Chiuve SE,et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes:a 22-year prospective study[J]. Arterioscler Thromb Vasc Biol,2016,36(11):2259-2267.
[23].Niinaga R,Yamamoto H,Yoshii M,et al. Marked elevation of serum M2BP-adiponectin complex in men with coronary artery disease[J]. Atherosclerosis, 2016,253:70-74.
[24].Perrotta F,Nigro E,Mollica M,et al. Pulmonary hypertension and obesity:focus on adiponectin[J]. Int J Mol Sci,2019,20(4).pii:e912.
[25].Arce-Cerezo A,García M,Rodríguez-Nuevo A,et al. HMGA1 overexpression in adipose tissue impairs adipogenesis and prevents diet-induced obesity and insulin resistance[J]. Sci Rep,2015,5:14487.
[26].de Rosa S,Chiefari E,Salerno N,et al. HMGA1 is a novel candidate gene for myocardial infarction susceptibility[J]. Int J Cardiol,2017,227:331-334.
[27].Kasmi L,Calderon J,Montreuil M,et al. Neurocognitive and psychological outcomes in adults with dextro-transposition of the great arteries corrected by the arterial switch operation[J]. Ann Thorac Surg,2018,105(3):830-836.
[28].Gleason LP,Deng LX,Khan AM,et al. Psychological distress in adults with congenital heart disease:focus beyond depression[J]. Cardiol Young, 2019,29(2):185-189.
[29].Stout KK,Daniels CJ,Aboulhosn JA,et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease:executive summary:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation,2019,139(14):e637-e697.
[30].Arzt M,Oldernburg O,Graml A,et al. Phenotyping of sleep-disordered breathing in patients with chronic heart failure with reduced ejection fraction-the SchlaHF registry[J]. J Am Heart Assoc,2017,6(12). pii:e005899.
[31].Oldernburg O,Wellmann B,Buchholz A,et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients[J]. Eur Heart J, 2016,37(21):1695-1703.
[32].[32]Sommerfeld A,Althouse AD,Prince J,et al. Obstructive sleep apnea is associated with increased readmission in heart failure patients[J]. Clin Cardiol, 2017,40(10):873-878.
[33].[33]Hooper L,Martin N,Abdelhamid A,et al. Reduction in saturated fat intake for cardiovascular disease[J]. Cochrane Database Syst Rev,2015,10(6):CD011737.
[34].Wang DD,Li Y,Chiuve SE,et al. Association of specific dietary fats with total and cause-specific mortality[J]. JAMA Intern Med,2016,176(8):1134-1145.
[35].Zhong VW,van Horn L,Cornelis MC,et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality[J]. JAMA,2019,321(11):1081-1095.
[36].Kim Y,Je Y. Dietary fibre intake and mortality from cardiovascular disease and all cancers:a meta-analysis of prospective cohort studies[J]. Arch Cardiovasc Dis, 2016,109(1):39-54.
[37].[37]Reynolds A,Mann J,Cumming J,et al. Carbohydrate quality and human health:a series of systematic reviews and meta-analyses[J]. Lancet,2019,393(10170):434-445.
相似文献/References:
[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[5]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(5):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[6]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[7]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[8]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[9]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(5):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[10]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
[11]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(5):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]